

Published in final edited form as:

Nature. 2016 November 03; 539(7627): 48–53. doi:10.1038/nature20122.

Arginine phosphorylation marks proteins for degradation by a Clp protease

Déborá Broch Trentini^{#1}, Marcin Józef Suskiewicz^{#1}, Alexander Heuck¹, Robert Kurzbauer¹, Luiza Deszcz¹, Karl Mechtler^{1,2}, and Tim Clausen¹

¹Research Institute of Molecular Pathology (IMP), Dr-Bohr-Gasse 7, 1030 Vienna, Austria

²Institute of Molecular Biotechnology of the Austrian Academy of Science (IMBA), Dr-Bohr-Gasse 3, 1030 Vienna, Austria

These authors contributed equally to this work.

Abstract

Protein turnover is a tightly controlled process that is crucial for the removal of aberrant polypeptides and for cellular signalling. Whereas ubiquitin marks eukaryotic proteins for proteasomal degradation, a general tagging system for the equivalent bacterial Clp proteases is not known. Here we describe the targeting mechanism of the ClpC–ClpP proteolytic complex from *Bacillus subtilis*. Quantitative affinity proteomics using a ClpP-trapping mutant show that proteins phosphorylated on arginine residues are selectively targeted to ClpC–ClpP. *In vitro* reconstitution experiments demonstrate that arginine phosphorylation by the McsB kinase is required and sufficient for the degradation of substrate proteins. The docking site for phosphoarginine is located in the amino-terminal domain of the ClpC ATPase, as resolved at high resolution in a co-crystal structure. Together, our data demonstrate that phosphoarginine functions as a bona fide degradation tag for the ClpC–ClpP protease. This system, which is widely distributed across Gram-positive bacteria, is functionally analogous to the eukaryotic ubiquitin–proteasome system.

Proteins destined for degradation are removed by energy-dependent proteases such as the eukaryotic proteasome or the bacterial Clp proteolytic complexes¹. In these tightly regulated protein shredders, the proteolytic sites are sequestered within an inner chamber that is only accessible through axial entrance gates². The gates are in turn guarded by regulatory AAA

Correspondence and requests for materials should be addressed to T.C. (clausen@imp.univie.ac.at).

Author Contributions D.B.T. performed mass spectrometry and biochemical experiments; M.J.S. performed the structural analysis and biochemical experiments; A.H. and R.K. performed *in vivo* complementation assays and biochemical experiments; L.D. assisted with biochemical experiments; T.C. designed the study with expert assistance from K.M. for the mass spectrometry part; D.B.T., M.J.S. and T.C. wrote the manuscript, with contributions from all authors.

Author Information Atomic coordinates and structure factors have been deposited in the Protein Data Bank (PDB) under accession code 5HBN. The mass spectrometry data have been deposited to the ProteomeXchange Consortium (<http://proteomecentral.proteomexchange.org>) with the dataset identifier PXD003305.

Reprints and permissions information is available at www.nature.com/reprints.

The authors declare no competing financial interests.

Readers are welcome to comment on the online version of the paper.

Reviewer Information *Nature* thanks S. Gygi, Y. Shi and the other anonymous reviewer(s) for their contribution to the peer review of this work.

(ATPases associated with diverse cellular activities) complexes that are responsible for recognizing substrate proteins as well as for unfolding and translocating them into the protease cage^{3,4}. In eukaryotes, substrate selection depends on a range of ubiquitin ligases that mark substrates with a polyubiquitin tag, a degradation signal recognized by the AAA regulatory particle of the 26S proteasome^{5,6}. An analogous system involving the protein modifier Pup targets substrates to the eukaryotic-like core proteasome present in mycobacteria and closely related species^{7,8}. However, it is not known whether the ATP-dependent Clp proteases, which are found in almost all bacteria, require a general post-translational tagging system. The Clp complexes are thought to use the N-terminal domains (NTD) of the AAA ATPases (ClpA, ClpC, ClpE or ClpX) to recognize specific degradation motifs, known as degrons, which are typically located at the N- or C-terminal ends of target proteins^{9–11}. These degrons can also be introduced by the specialized SsrA tagging system, which is used for rescuing stalled ribosomes¹². Alternatively, substrate recruitment may be aided by adaptor proteins that tether selected substrate proteins to the Clp proteolytic complex, thus facilitating their degradation⁹.

In *B. subtilis* and other Gram-positive bacteria, the ClpC–ClpP (ClpCP) protease, which is constituted by the AAA unfoldase ClpC and the protease ClpP, is an important proteolytic machine for eliminating unfolded and aggregated proteins. The ClpCP proteolytic complex is under the control of McsB, the founding member of a class of protein kinases targeting arginine residues¹³. First, McsB controls the amounts of ClpCP in the cell by phosphorylating and inhibiting the transcriptional repressor CtsR^{13–15}, which in turn regulates *clpC* and *clpP* gene expression¹⁶. Second, McsB has been reported to function as an adaptor protein of ClpC by stimulating its ATPase activity and promoting degradation of the CstR substrate^{17,18}. In addition to regulating CtsR and ClpC, McsB phosphorylates hundreds of diverse proteins *in vivo*, as revealed by *B. subtilis* phosphoproteomic analyses^{15,19}. This promiscuous activity suggested a more general function of the protein arginine kinase in the stress response of Gram-positive bacteria.

ClpCP degrades pArg proteins *in vivo*

Arginine residues are frequently observed at molecular interfaces crucial for protein folding and assembly²⁰. Therefore, arginine phosphorylation, resulting in a net-charge inversion, is predicted to have a strong effect on protein stability. Of note, the kinase catalysing this reaction, McsB, has many substrates *in vivo* and is transcriptionally co-regulated with ClpP, the major protease of *B. subtilis*. We thus proposed that arginine phosphorylation may have a direct role in the degradation of aberrant proteins. To test this assumption, we monitored the fate of phosphoarginine (pArg) proteins *in vivo* by expressing an inactive trapping variant of the ClpP protease (Ser98Ala, ClpP^{TRAP}; refs 10,21). Substrates captured within the protease cage can be co-purified and analysed by mass spectrometry (MS). To perform the pull-down experiments in the wild-type *B. subtilis* background, we engineered a ClpP mutant that does not interact with the endogenous, active protease. For this purpose, we exchanged residues of an ion pair at the interface of the ClpP heptamer. The resulting cross mutant (Glu119Arg/Arg142Glu, ClpPX) did not form heterooligomers with wild-type ClpP, but maintained the ability to assemble a substrate-trapping cage (Extended Data Fig. 1).

Quantitative MS analysis of ClpP pull-downs from heat-shocked bacteria (Extended Data Fig. 2a, b, strategy illustrated in Fig. 1a) revealed a large number of proteins that were specifically captured by the ClpPX-TRAP mutant (Fig. 1b and Supplementary Table 1). Despite the technical difficulties in identifying arginine phosphorylations¹⁵, we detected 13 pArg proteins among the 233 isolated ClpP substrates (Extended Data Table 1, Supplementary Table 2). Taking into account the functional connection between McsB and ClpC, which are found in the same operon, we next asked whether pArg proteins are transferred into the ClpP cage by ClpC. To this end, we performed ClpPX-TRAP pull-down analyses from wild-type and *clpC* knockout (*clpC*) cells in parallel. Whereas we observed 14 pArg proteins in the pull-downs performed in wild-type cells, the pull-downs in *clpC* cells revealed only a single pArg substrate (Fig. 1c, Extended Data Table 1). Of note, this substrate, CtsR, was also shown to be targeted to ClpP by the ClpX and ClpE unfoldases^{22,23}. The almost complete absence of ClpP-trapped pArg proteins in *clpC* bacteria is even more remarkable, as the deletion of ClpC increases the overall amounts of pArg proteins. Despite the presence of YwlE, a highly active arginine phosphatase preventing pArg identification in *B. subtilis* wild-type cells^{15,19,24}, phosphoproteomics analysis of *clpC* cell lysates revealed 25 pArg sites (Supplementary Table 3). This finding highlights the active role of ClpC in directing pArg proteins to ClpP-dependent proteolysis. Consistent with the proposed model, *clpC* *B. subtilis* cell extracts also accumulated pArg proteins (Supplementary Table 4). To estimate the fraction of pArg proteins among the ClpP substrates, we analysed the overlap of the ClpP degradome (as defined by our pull-down experiments) and the pArg proteome (sites detected previously^{15,19,25} and in the *clpP* mutant strain). Accordingly, 25% of the proteins degraded by ClpP are substrates of McsB and thus potential candidates of the pArg-dependent degradation pathway (see also Supplementary Discussion and Extended Data Fig. 2c).

Protein phosphorylation stimulates ClpCP

To analyse how ClpC selects pArg-containing substrates, we reconstituted the ClpCP–McsB system *in vitro*. McsB was previously described as an adaptor of ClpC targeting the transcriptional repressor CtsR for ClpCP-mediated proteolysis^{17,18}. Although the kinase activity of McsB was shown to be required for CtsR degradation, it was not clear whether McsB itself, the substrate or the ClpCP protease became phosphorylated, and how this phosphorylation event enhanced protease activity. We thus recapitulated the corresponding kinase and protease assays using the intrinsically unfolded protein β -casein as a model substrate. We observed that the ClpCP protease complex alone was not active. However, in the presence of MecA, a well-characterized ClpC adaptor²⁶, the substrate was efficiently hydrolysed (Fig. 2a). Similarly, McsB induced the degradation of β -casein by ClpCP. The stimulatory effect was enhanced by the MscB activator McsA²⁷, which showed no effect on casein degradation by itself (Fig. 2a). To test whether the kinase activity of McsB is required for β -casein degradation, we used an inactive mutant of McsB (Glu212Ala; ref. ¹³), and, in parallel, probed the effect of the YwlE arginine phosphatase. Both kinase inactivation and phosphatase addition prevented substrate degradation (Fig. 2b, c), highlighting the importance of the arginine kinase activity of McsB for activating the ClpCP protease. This

functional coupling is also reflected in the different kinase activities of the tested McsB variants (Fig. 2a).

pArg is a degradation tag for ClpCP

To explore the stimulatory effect of McsB further, we performed degradation assays in the presence of the free amino acid phosphoarginine (pArg^{AA}, with AA denoting the amino acid). We reasoned that pArg^{AA} may compete with, and thus reveal, the pArg-dependent activation event. When incubated with McsB and ClpCP, pArg^{AA} reduced the rate of β -casein degradation (Fig. 3a). We next explored the influence of pArg^{AA} on β -casein degradation by the ClpCP–MecA complex that should operate in a phosphorylation-independent manner. Unexpectedly, however, pArg^{AA} also inhibited (and to a greater extent) the activity of the MecA-stimulated ClpCP protease (Fig. 3b). By contrast, unphosphorylated arginine or phosphate did not block degradation. As it is known that effector proteins such as MecA dock to the NTD of AAA unfoldases, we monitored how pArg^{AA} influences this interaction (Fig. 3c). A pull-down experiment using the NTD of ClpC (ClpC^{NTD}) revealed that pArg^{AA} inhibits the association between MecA and ClpC, probably by competing with MecA for the same binding site. When probing the direct interaction between pArg^{AA} and ClpC by isothermal titration calorimetry (ITC), we measured dissociation constants (K_d values) of 60 μ M for full-length ClpC and 13 μ M for the isolated NTD (Fig. 3d). The pronounced specificity for pArg^{AA} was confirmed by measuring the interaction with related compounds, which did not bind (pTyr^{AA}, arginine) or did so only weakly (phosphate). Moreover, we observed that pArg^{AA} did not bind to MecA, and has a very low affinity (K_d > 1 mM) for McsB (Extended Data Fig. 3). Finally, we tested the binding of pArg^{AA} to the NTD of ClpA, the closest homologue of ClpC in Gram-negative bacteria, which lack a protein arginine kinase. Because no binding was observed (Extended Data Fig. 3), the ability to recognise pArg^{AA} with high specificity seems to be a unique property of the ClpC unfoldase.

The pArg-binding site of ClpC could have two possible functions in protein degradation. It could serve as a docking site for the autophosphorylated form of McsB, which functions as an adaptor, or, alternatively, it could directly recognize pArg-containing substrates. To distinguish between these two possibilities, we enzymatically prepared pArg-modified β -casein (casein^{pArg}) (Fig. 4a and Extended Data Fig. 4). A pull-down assay showed that casein^{pArg}, but not unphosphorylated casein, binds to the ClpC^{NTD} (Fig. 4b). Because inhibition of the casein^{pArg}–NTD association required an excess of pArg^{AA}, it seems that a pArg residue in a protein context interacts more strongly with the NTD than the free phospho amino acid. When testing casein^{pArg} as a direct ClpCP substrate, we observed that the ClpCP protease could degrade casein^{pArg} even in the absence of McsB or MecA (Fig. 4c). These data suggest that the assembly of the functional ClpCP protease can proceed without adaptor proteins. To corroborate this surprising finding, we performed ClpC and ClpP pull-down experiments after incubation with substrate. Consistent with the degradation assays results, we observed the formation of a transient ClpCP complex in the presence of casein^{pArg}, even to a higher degree than in the presence of MecA. Conversely, unphosphorylated casein could not promote ClpCP assembly (Fig. 4d). Together, these data

show that the pArg modification is crucial for recruiting substrates to the NTD of ClpC and for promoting assembly of the functional ClpCP protease complex.

To confirm the role of pArg as a degradation signal for the ClpCP protease, we analysed the digestion of substrate proteins that were arginine-phosphorylated to different degrees. For this purpose, we pre-incubated β -casein with McsB for increasing time intervals (Fig. 4e). ClpCP degradation assays of the resulting casein/casein^{pArg} mixtures showed a direct correlation between the amount of phosphorylated substrate and the extent of degradation (Fig. 4e and Extended Data Fig. 4e). Consistently, adding YwIE phosphatase to the pArg-modified substrates abolished their degradation. These results unambiguously demonstrate that ClpCP selectively degrades casein^{pArg} and does not recognize pArg-less proteins as substrates.

The pArg docking sites of ClpC

To visualize how pArg binds to ClpC, we performed co-crystallization experiments of the NTD from *B. subtilis* ClpC with pArg^{AA}. The co-crystal structure was determined at 1.6 Å resolution (Extended Data Table 2) and, consistent with the symmetrical nature of the NTD protein fold²⁸ (Fig. 5a), revealed two almost identical pArg-binding sites (Fig. 5b, c). Mapping the electrostatic potential of the NTD on its molecular surface illustrates the ‘bipolar’ architecture of the pArg-binding site that distinguishes it from pSer/Thr or pTyr binding sites (Extended Data Fig. 5). Such organization is perfectly suited for simultaneously recognizing the positively charged guanidinium and the negatively charged phosphoryl group. The functional importance of the pArg recruitment is reflected by the exact conservation of the interacting residues in ClpC proteins from other Gram-positive species (Extended Data Fig. 6). Since the structural data suggest that the ClpC hexamer has 12 pArg-docking sites, we asked how many pArg tags per substrate are required for degradation. Native MS analysis of the casein^{pArg} sample that resulted from prolonged incubation with McsB and that was completely degraded after ClpCP incubation revealed a mixture of mono- and di-phosphorylated molecules (Extended Data Fig. 7). Given the efficiency of also cleaving less phosphorylated substrates (Fig. 4f), we suppose that proteins carrying a single pArg mark can be degraded by ClpCP.

Notably, the identified pArg-binding sites match the MecA-binding grooves observed in the MecA–ClpC complex²⁹, with the phosphoryl moieties of pArg^{AA} binding in place of the MecA glutamate residues 184 and 198 (Fig. 5d). This overlap explains the inhibition of MecA–ClpCP by pArg^{AA}, as observed in our functional studies. Importantly, pArg^{AA} binds to ClpC glutamate residues 32 and 106, which in the MecA–ClpC complex remain unbound. Therefore, the bipolar architecture of the pArg-binding sites can only be fully explored by the phosphoguanidinium moiety, whereas the MecA glutamate residues only dock into the positively charged half. To test the structurally characterized binding mode experimentally, we prepared NTD mutants carrying a Glu32Ala/Glu106Ala double mutation (EA) and measured the interaction with MecA and pArg^{AA}. As predicted, mutating the two glutamate residues abolished pArg^{AA} binding (Extended Data Fig. 3) but did not impair the interaction with MecA (Fig. 3c). Consistent with the binding data, the corresponding ClpCP^{EA} protease efficiently degraded protein substrates with the help of MecA but failed to degrade substrates

in a pArg-dependent manner (Fig. 5e, f). To confirm the selective failure in recognizing and degrading pArg protein, we measured the ClpC ATPase activity, which, in analogy to other AAA unfoldases³⁰, should be stimulated by substrates. We observed that purified casein^{pArg} could stimulate the ATPase activity of wild-type ClpC to a similar extent to MecA (Fig. 5g). In strong contrast, the ATPase of the ClpC^{EA} mutant could be induced by MecA, but not by casein^{pArg}, confirming the selective loss of pArg-dependent functions in this mutant.

Biological role of the pArg–ClpCP system

The developed ClpC^{EA} mutant represents a valuable tool for addressing the biological role of pArg-dependent protein degradation. To this end, we analysed the ability of the ClpC^{EA} mutant to suppress growth defects of a *clpC* strain at increased temperatures (Fig. 6a). Whereas the expression of wild-type ClpC from a plasmid restored thermotolerance and even made the bacteria more robust in surviving increased temperatures, expression of the ClpC^{EA} mutant could not rescue the bacteria. As the ClpC^{EA} mutant is fully functional as a protease and can team up with adaptor proteins, these data highlight the essential role of the pArg-dependent degradation pathway in surviving proteotoxic stress situations.

Discussion

Energy-dependent proteases are essential for all living organisms to carry out protein quality control and degrade short-lived regulatory proteins. In contrast to eukaryotes, which universally use polyubiquitin chains for marking target proteins, a general post-translational modification regulating proteolysis in bacteria is not known. Here, we characterize such a tagging system. We show that pArg is a degradation mark for the ClpCP proteolytic machine, present in most Gram-positive species. Despite differing in size, the bacterial pArg modifier shares several features with the eukaryotic polyubiquitin degradation tag. First, both pArg and polyubiquitin are post-translationally attached to substrates, allowing for dynamic regulation of degradation that is not available to mechanisms relying on sequence-encoded degrons. Second, the pArg mark is recognized by highly specific receptor sites on the NTD of ClpC (Fig. 6b), as is ubiquitin by special receptor proteins of the 19S regulatory particle. Third, owing to charge inversion, the phosphorylation of arginine residues is predicted to destabilize the native structure of substrate proteins, priming them for subsequent catalysed unfolding. Similarly, the polyubiquitin tag affects the structure and stability of marked proteins³¹. Fourth, the pArg tag is reversibly attached to substrate proteins. As enzymes building polyubiquitin chains are opposed by de-ubiquitinases, the activity of the McsB kinase is counteracted by the pArg-specific phosphatase YwIE, thus allowing for regulation of the pArg degradation pathway.

In addition to revealing the pArg degradation tag, our study clarifies the mechanism of the ClpCP protease. Notably, ClpC has been reported to be a unique AAA enzyme that requires accessory proteins to assemble its functional hexameric form³². The present data suggest that this model is not fully correct, as the degradation of pArg-containing substrates does not require any additional co-factors. Substrate recruitment itself induces the ATPase activity of ClpC and promotes assembly of the functional ClpCP complex. Similar to the eukaryotic 26S proteasome, binding of specifically marked substrates is thus directly linked to protease

activation. On the basis of the described functional similarities, the discovered pArg–ClpCP system seems to represent a simple bacterial version of the eukaryotic ubiquitin–proteasome system.

Our study also provides important insights into the biological role of pArg as a degradation tag. Analysis of the *in vivo* ClpP degradome suggests that the pArg tag is crucial not only for the regulatory proteolysis of CtsR but also for general turnover of structurally and functionally diverse proteins. Furthermore, we observed that pArg-dependent protein degradation is vital for coping with proteotoxic stress (Fig. 6a), and that pArg proteins are markedly enriched in the aggregate fraction of *B. subtilis* cells (Supplementary Tables 4 (*clpP*) and 5 (wild-type)). Of note, 50% of the *in vivo* phosphorylated proteins^{15,19} carry the phosphomark in a region predicted to adopt a defined secondary structure, that is, in an α -helix or β -strand. Presumably, these sites would only be accessible to McsB when present in an at least partially unfolded state, indicating that McsB might target the damaged form of those proteins. Consistent with this, a recent *in vivo* study points to the importance of the McsB kinase for removing aberrant proteins in *B. subtilis*: the deletion of the kinase led to the accumulation and aggregation of an unstable model protein, while the levels of a stably folded counterpart of this model protein were not influenced³³. We thus presume that protein arginine phosphorylation may have a role in the quality control of bacterial proteins, targeting unstable and aggregation-prone proteins for ClpCP degradation. Modifying arginine of all amino acids to decide about the fate of aberrant proteins seems to make sense. As arginine-rich patches correlate with aggregation propensity³⁴, adding a phosphoryl group to arginine residues could hinder aggregation and, at the same time, promote the clearance of such problematic protein species by co-working protease machines.

Methods

DNA construct design

For recombinant protein overexpression in *Escherichia coli*, the *clpP*, *mcsA*, *mcsB*, *clpC* and *clpC¹⁻¹⁵⁰* (NTD) genes/fragments from *B. subtilis* and *clpA¹⁻¹⁵⁰* (NTD) from *E. coli* were cloned into pET21 or pET SUMO vectors (Novagen) conferring a terminal hexahistidine (6His) tag. Previously published pET21-derived plasmids were used for the expression of *Geobacillus stearothermophilus* McsB, YwlE and YwlE^{D118N} proteins^{13,24,25}. For protein expression in *B. subtilis*, genes were cloned into the vector pHCMC05 (ref. 35) that contains the Psac IPTG-inducible promoter. For the expression of the ClpP, ClpP^{TRAP(S98A)}, ClpP^{X(E119A/R142E)}, ClpP^{X-TRAP(S98A/E119A/R142E)}, ClpC and ClpC^{EA(E32A/E106A)}, a C-terminal 6His tag including a Leu-Glu linker was introduced by PCR amplification. Single point mutations were generated using the QuikChange II mutagenesis kit (Agilent Technologies).

B. subtilis strains

The pHCMC05 plasmids described above were transformed into wild-type *B. subtilis* (strain 168) (ATCC 2385). To generate ClpC-knockout (*clpC*) bacteria, genomic DNA from a *B. subtilis clpC::tet* strain³⁶ was transformed into the *B. subtilis* strains containing the pHCMC05, pHCMC05-clpP^X, pHCMC05-clpP^{X-TRAP}, pHCMC05-ClpC or pHCMC05-

ClpC-E32A-E106A plasmids. The disruption of *clpC* in the resulting strains was confirmed by sequencing. A previously published *B. subtilis clpP::spec^R* (ref. 37) strain was used to grow ClpP-knockout bacteria for phosphoproteomic analysis.

Culture procedures

All bacterial cultures were grown in Luria–Bertani (LB) medium. For the *B. subtilis clpC* and *clpP* strains, tetracycline (10 µg ml⁻¹) and spectinomycin (100 µg ml⁻¹) were added, respectively. *E. coli* and *B. subtilis* cultures containing the pHCMC05-derived plasmids were cultured in the presence of ampicillin (50 µg ml⁻¹) and chloramphenicol (10 µg ml⁻¹), respectively. *E. coli* BL21 (DE3) containing pET21- or pET SUMO-derived vectors were cultured in the presence of ampicillin (50 µg ml⁻¹).

In vivo pull-downs using ClpP trapping mutants

For the ClpP^X-TRAP pull-down experiment in the wild-type background of *B. subtilis* (Fig. 1b), 6 independent *B. subtilis* cultures were grown in LB media expressing either ClpP^X (3 control cultures to identify unspecific binding partners) or ClpP^X-TRAP (3 sample cultures). After the cells were grown at 37 °C until mid-exponential phase, expression of His-tagged ClpP^X or ClpP^X-TRAP proteins was induced with 1 mM IPTG. Recombinant protein expression proceeded for 3 h at 37 °C. To induce the activity of heat-shock proteins, including McsB and various Clp ATPases, the cultures were incubated in a pre-warmed incubator at 45 °C for 45 min. Cells were collected by centrifugation, resuspended in lysis buffer (25 mM Tris, pH 7.5, 150 mM NaCl, 10% glycerol) and stored at -80 °C. For the pull-down experiment comparing ClpP-trapped proteins in wild-type and *clpC* backgrounds (Fig. 1c), the same procedure was applied using 12 independent *B. subtilis* cultures (3 wild type with ClpP^X, 3 wild type with ClpP^X-TRAP, 3 *clpC* with ClpP^X, 3 *clpC* with ClpP^X-TRAP).

The thawed cell suspensions were incubated for 1 h on ice with 2 mg ml⁻¹ lysozyme (Sigma), Complete protease inhibitor cocktail (Roche), 0.2 mM PMSF (Sigma) and 10 µg ml⁻¹ DNase (Sigma). Cells were sonicated and the resultant lysate was cleared by centrifugation at 4 °C. For the purification of 6His-tagged ClpP, the lysate was incubated with Dynabeads His-Tag Isolation & Pulldown (Invitrogen) for 1 h at 4 °C. The beads were then washed 5× with lysis buffer and 2× with lysis buffer containing 50 mM imidazole. Two aliquots (5 or 10%) of the resulting beads were collected for SDS–PAGE analysis (protein elution with denaturing SDS–PAGE sample buffer) or Tris-acetate native-PAGE (protein elution with lysis buffer containing 500 mM imidazole). The remaining beads were subjected to reduction with 2 mM DTT (56 °C, 40 min), alkylation with 10 mM iodoacetamide (room temperature, in the dark, 45 min), and digestion with 2.5 µg Trypsin Gold (Promega) at 37 °C for 12 h.

MALDI-MS analysis of ClpP purifications

To analyse the mass of *B. subtilis* proteins co-purifying with ClpP(6His) under heat-shock conditions (Extended Data Fig. 1), matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI–TOF-MS) was performed. The corresponding protein purifications were spotted on a MALDI plate using a sinapinic acid (10 mg ml⁻¹) matrix

prepared in 50% acetonitrile (ACN) and 0.1% trifluoroacetic acid (TFA). The samples were measured in a 4800 MALDI-TOF-TOF (AB Sciex) instrument operated in linear mode. Calibration was performed internally using cytochrome C as standard.

Sample preparation for phosphoproteomic analysis

For the phosphoproteomic analysis of total cell extracts of *B. subtilis clpC*, cells were lysed by sonication in buffer 4% SDS, 100 mM Tris, pH 7.5, 100 mM DTT and further processed using a filter aided sample preparation (FASP)³⁸ modified method, as described previously¹⁵, followed by trypsin digestion at 37 °C for 12–16 h. Protein aggregates were dissolved in the SDS buffer and processed in the same manner. Trypsin digestion completion was inspected by retention time and UV intensity (214 nm) distribution upon reverse-phase high-performance liquid chromatography (RP-HPLC) separation of a 0.1% aliquot of the resulting supernatants on a monolithic column (Ultimate Plus equipped with a PepSwift PS-DVB column, 5 cm × 200 μm, Dionex-Thermo-Fisher).

For the ClpP *in vivo* pull-down assays, a small aliquot (0.5%) of the on-bead trypsin digests was collected for subsequent quantitative analyses of co-purified proteins. The biological replicates were then pooled and further processed for phosphorylation analysis. Before phosphopeptide enrichment, sample digests were purified from buffer reagents by RP-C18 solid phase extraction at neutral pH using Oasis HLB cartridges (Waters). A previously described TiO₂ protocol¹⁵, optimized in accordance to the acid-labile nature of phosphoarginine, was used for phosphopeptide enrichment.

LC-MS/MS analysis

Reverse-phase separation of all peptide mixtures was carried out on an Ultimate 3000 RSLC nano-flow chromatography system (Thermo Scientific), using 0.5% acetic acid (pH 4.5 with NH₃) as loading solvent, to prevent phosphoarginine hydrolysis during removal of salts in the pre-column (PepMapAcclaim C18, 5 mm × 0.3 mm, 5 μm, Thermo Scientific). Peptide separation was achieved on a C18 separation column (PepMapAcclaim C18, 50 cm × 0.75 mm, 2 μm, Thermo Scientific) by applying a linear gradient from 2% to 35% solvent B (80% ACN, 0.08% formic acid) in 120 or 240 min (pull-down and total extract samples, respectively) at a flow rate of 230 nl min⁻¹. Solvent A was 2% ACN, 0.1% formic acid. The separation was monitored by UV detection and the outlet of the detector was directly coupled to the nano-Electrospray ionization source (Proxeon Biosystems) for MS analysis.

For phosphorylation analysis, TiO₂ elution samples were infused into the LTQ Orbitrap Velos Pro ETD mass spectrometer (Thermo Scientific) using PicoTip nanospray emitter tips (New Objective) at a voltage of 1.5 kV. Peptides were analysed in data-dependent fashion in positive ionization mode, applying two different fragmentation methods: collision-induced dissociation (CID) and electron-transfer dissociation (ETD). The survey scan was acquired at resolution 60,000 and the 6 most abundant signals with charge state equal or higher than 2+ and exceeding an intensity threshold of 1,500 counts were selected for peptide fragmentation analysis. For MS/MS experiments, precursor ions were isolated within a 2.1-Da window centred on the observed *m/z*. To prevent repeated fragmentation of highly abundant peptides, selected precursors were dynamically excluded for 30 s from MS/MS

analysis. CID fragmentation was achieved at normalized collision energy (NCE) of 35% with additional activation of the neutral loss precursor at M-49, M-32.7 and M-98 AMU in a standard multistage activation method. For ETD, peptides were incubated with fluoranthene anions allowing for charge-state-dependent incubation times (90 ms for 3+ charged peptides), and resulting peptide fragments were detected in the ion trap analyser.

For the identification of co-purified proteins in the ClpP *in vivo* pull-down assays, slightly different instrument settings were used. The 12 most abundant signals with charge state equal to or higher than 2+ and exceeding an intensity threshold of 500 counts were selected for CID peptide fragmentation analysis, applying an isolation window of 2 Da. Multistage activation was disabled. Selected precursors were dynamically excluded for 60 s from MS/MS analysis. Each pull-down digest was analysed twice, to evaluate technical reproducibility.

MS data analysis

For the phosphorylation analysis of TiO₂-enrichment samples, raw data were extracted by the Proteome Discoverer software suite (version 1.4.0.288, Thermo Scientific) and searched against a combined forward/reversed database of *B. subtilis* Uniprot Reference Proteome with common contaminants added (4,455 entries in total) using MASCOT (version 2.2.07, Matrix Science). Carbamidomethylation of cysteine was set as fixed modification. Phosphorylation of serine, threonine, tyrosine and arginine plus oxidation of methionine were selected as variable modifications. Since tryptic cleavage is impaired at phosphorylated arginine, a maximum of two missed cleavage sites was allowed, whereas fully tryptic cleavage of both termini was required. The peptide mass deviation was set to 5 p.p.m.; fragment ions were allowed to have a mass deviation of 0.8 Da. False discovery rates were assessed using the Percolator tool³⁹ within the Proteome Discoverer package. The results were filtered for peptide rank 1 and high identification confidence, corresponding to a 1% false discovery rate. Low-scoring peptides (Mascot ion score < 20) were manually verified. In the rare cases in which a peptide was mapped to more than one protein sequence, both protein hits are reported. For reliable phosphorylation site analysis, all phosphopeptide hits were automatically re-analysed by the phosphoRS software⁴⁰ within the Proteome Discoverer software suite. All the phosphopeptides identified in the ClpP *in vivo* pull-down assays were manually inspected. For other samples, we considered a phosphorylation site to be localized when the reported phosphoRS probability was higher than 90%. When multiple peptide-spectrum matches (PSMs) were obtained for the same phosphopeptide, only the PSM presenting the best identification/localization score compromise is presented. The multiple redundant PSMs were ranked according to their phosphoRS probability score into three categories (90–94%, 94–97% and 97–100%); the PSM presenting the best Mascot score within the highest phosphoRS category achieved was reported. PSMs presenting wrong or inconclusive localizations were thus excluded from the final list of phosphopeptides. Multiply phosphorylated peptides were also excluded from the analysis, because they cannot be classified into ‘phosphorylation type’ categories.

For quantitative analysis of ClpP-trapped proteins, MS data were analysed using the MaxQuant software environment⁴¹, version 1.5.1.2, and its built-in Andromeda search

engine⁴², against the *B. subtilis* Uniprot database described above. Strict trypsin specificity with up to two missed cleavages was used. The minimum required peptide length was set to six amino acids. Carbamidomethylation of cysteine was set as a fixed modification and *N*-acetylation of proteins N termini (42.010565 Da) and oxidation of methionine were set as variable modifications. During the main search, parent masses were allowed an initial mass deviation of 4.5 p.p.m. and fragment ions were allowed a mass deviation of 0.5 Da. The mass accuracy of the precursor ions was improved by time-dependent recalibration algorithms of MaxQuant. The ‘match between runs’ option was enabled to match identifications across samples within a time window of 2 min of the aligned retention times. The second peptide identification option in Andromeda was enabled. PSM and protein identifications were filtered using a target–decoy approach at false discovery rate of 1% for PSMs and 5% for proteins. Relative, label-free quantification of proteins was done using the MaxLFQ algorithm⁴³ integrated into MaxQuant using default parameters. Unique and razor peptides were considered for quantification.

Statistical evaluation of the resulting protein quantifications was performed using R scripting. Proteins quantified in less than 50% of the samples were filtered out. Missing LFQ values were substituted by the lowest value observed in the corresponding sample. For each protein, the fold change of LFQ-averaged intensities (ratio ClpP^{TRAP}/control) and the corresponding *P* value (Limma test; Linear Models for Microarray Data) were calculated. A protein was considered to be a ClpP substrate when it was found to be enriched in the TRAP pull-down assays by a factor of at least 2 and *P* < 0.05. The ‘protein groups’ output file from MaxQuant containing the statistical evaluation is available in Supplementary Table 1. The mass spectrometry data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository⁴⁴ (<http://proteomecentral.proteomexchange.org>). Representative spectra of the pArg peptides identified in the ClpP trapping mutant pull-downs are presented in Supplementary Fig. 1.

Expression and purification of recombinant proteins

For the overexpression of recombinant proteins in *E. coli* BL21 (DE3), LB cultures were grown at 37 °C until the exponential phase, when expression was induced with 0.5 mM IPTG. After expression, cells were collected by centrifugation, resuspended in buffer A and stored at –80 °C. As the *B. subtilis* ClpC protein was unstable when expressed in *E. coli*, the production of wild-type ClpC(6His) and ClpC^{EA}(6His) was performed in *B. subtilis* containing the corresponding pHCMC05 plasmids, by induction with 1 mM IPTG for 3 h at 37 °C. The optimal expression strategies and purification buffers are summarized in Extended Data Table 3.

Cell suspensions were incubated on ice for 30 min in the presence of 1 mg ml⁻¹ lysozyme, 0.1 mM PMSF, 10 µg ml⁻¹ DNase and sonicated. Lysates were cleared by centrifugation and loaded on a 5 ml Ni- or Co-NTA column (GE Healthcare LifeSciences) equilibrated in buffer A. Washes were performed using a step-wise imidazole gradient, typically starting with 25 mM. The His-tagged proteins were eluted with buffer A containing 250 mM imidazole and concentrated using Vivaspin devices (Sartorius Stedim Biotech). Constructs expressed as a SUMO-fusion (SUMO-ClpP and SUMO-MecA) were incubated with SUMO

Protease (Thermo Fisher Scientific) to obtain tag-free versions of the proteins. All resulting proteins were further purified by gel filtration on a Superdex-75 or -200 column (GE Healthcare LifeSciences) equilibrated with buffer B. For the purification of McsA(6His), the full-length protein was separated from an abundant cleavage product by ion exchange on a MonoQ column (GE Healthcare LifeSciences) using a 0.1–1 M NaCl gradient in 50 mM Tris, pH 8.5, 1 mM TCEP. All proteins were aliquoted and stored at -80°C until further use.

For the purification of the *B. subtilis* ClpC NTD and NTD^{EA} mutant, affinity, ion exchange, and size exclusion chromatography were carried out in a 0.5× PBS buffer (6 mM Na/K phosphate, pH 7.25, 1.35 mM KCl, 68.5 mM NaCl). After elution from Ni-NTA using the PBS buffer supplemented with 250 mM imidazole, the protein was passed through a ResourceQ column (GE Healthcare LifeSciences). This was followed by gel filtration on a Superdex 200 column (GE Healthcare LifeSciences).

***In vitro* pull-down assays**

Varying amounts of the analysed components (individual proteins, pArg^{AA}) were incubated in 200 μl of reaction buffer (10 mM Tris, pH 8.0, 50 mM NaCl, 5 mM MgCl₂ and 25 mM imidazole). After 5 min, 50 μl of Ni-Sepharose was added to capture His-tagged proteins. Sepharose was washed three times with 200 μl reaction buffer and bound proteins were eluted with 50 μl of elution buffer (10 mM Tris, pH 8.0, 50 mM NaCl, 5 mM MgCl₂ and 1 M imidazole). For visualization, input and elution, fractions were analysed by SDS–PAGE.

Native-PAGE

For the analysis of the oligomeric state of purified ClpP samples, a Tris-acetate non-denaturing PAGE system was used. Gel composition corresponded to 7, 10 or 15% acrylamide, 0.24% bis-acrylamide, 200 mM Tris-acetate, pH 7, polymerized in the presence of 0.042% ammonium persulfate (APS) and 0.125% N,N,N',N'-tetramethylethylenediamine (TEMED). The running buffer composition was 25 mM Tris-HCl, 192 mM glycine, pH 8.3. Protein separation was performed at 4 $^{\circ}\text{C}$ and 150 mV for 3–4 h, and proteins were visualized by Coomassie-based InstantBlue protein stain (Expedeon). The NativeMark unstained protein standard (Thermo Fisher Scientific) was used for the estimation of ClpP oligomeric state.

Purification of casein^{pArg}

To produce the arginine-phosphorylated substrate, β -casein from bovine milk (Sigma) was incubated at 10 μM (all protein concentrations, if not otherwise mentioned, are for a single protomer) with 2 μM McsB and McsA from *B. subtilis* in 25 mM Tris, pH 7.5, 50 mM NaCl, 20 mM MgCl₂, and 5 mM ATP at 30 $^{\circ}\text{C}$ for 2 h. The reaction mixture was concentrated with a Vivaspin device and applied to a Superdex-200 size exclusion column equilibrated with 25 mM Tris, pH 7.5, 50 mM NaCl. The fractions most strongly enriched in β -casein over McsB (Extended Data Fig. 5a) were then pooled, concentrated and stored at -80°C . The presence of the pArg modification was confirmed by immunoblotting using a pArg-specific antibody as described below.

To obtain casein^{pArg} of higher purity, a similar phosphorylation reaction was performed, except that 4 μM of the *G. stearothermophilus* McsB(6His) was used instead of the *B. subtilis* McsBA complex. The reaction mixture was afterwards applied to a Ni-NTA column (GE Healthcare LifeSciences) to reduce the amounts of the His-tagged McsB before the final gel filtration purification step (Extended Data Fig. 5c).

To prepare β -casein phosphorylated to different degrees (Fig. 4e), a large-scale phosphorylation reaction was set-up with the *B. subtilis* McsBA at 30 °C. An aliquot (time 0) was collected before the addition of ATP. After adding ATP, aliquots were taken after 10, 30, 60 and 120 min. After adding 100 mM EDTA (to stop phosphorylation), each aliquot was concentrated by Vivaspin ultrafiltration and applied to a Superdex 200 size exclusion column. An additional sample, which was collected after 120 min incubation with McsBA, was treated with 1 μM YwIE arginine phosphatase for 2 h. The phosphatase was then inactivated by adding 2 mM pervanadate and the sample was concentrated and submitted to size exclusion chromatography. The different casein^{pArg} preparations were concentrated and stored at -80 °C.

To quantify the increase of arginine phosphorylation over time, a western blot was performed using the pArg-specific antibody described previously²⁴. The casein^{pArg} preparations (2 μg) were separated by SDS-PAGE, transferred to a nitrocellulose membrane and fixed using a 0.4% formaldehyde solution in PBS, pH 7.5, for 30 min as previously described⁴⁵. After blocking, the pArg-specific primary antibody (2 $\mu\text{g ml}^{-1}$, Morphosys AG) was incubated overnight at 4 °C and the secondary antibody (goat anti human IgG F(ab')₂:HRP, AbD Serotec) was used at a 1:7,000 dilution for 1.5 h at room temperature. The detection was performed using ECL Plus western blotting substrate (Pierce). The signals were quantified using the ImageJ software⁴⁶ and normalized to the band intensities observed in a coomassie-stained SDS-PAGE gel replicate having 1.3 μg of each protein preparation.

ClpCP *in vitro* degradation assays

In vitro degradation assays containing 0.16 μM ClpC (hexamer), 0.16 μM ClpP (heptamer) and 5 μM β -casein substrate were performed in 25 mM Tris, pH 7.5, 150 mM NaCl, 20 mM MgCl₂ and 5 mM ATP at 30°C. A different β -casein concentration (10 μM) was used, for better resolution, when comparing ClpCP and ClpCP^{EA} in MecA-dependent degradation. Small molecule compounds, for example, phospho-L-arginine (pArg^{AA}, Toronto Biochemicals), L-arginine (Sigma) or sodium phosphate, pH 7.5, were added at 1 mM. Time-point aliquots were mixed with denaturing SDS-PAGE sample buffer containing 100 mM EDTA to stop the reaction and analysed by SDS-PAGE. The resulting gels were stained with InstantBlue dye (Expedeon) and quantified using ImageJ⁴⁶. Supplementary Fig. 2 shows full SDS-PAGE gels and corresponding quantifications of Figs 2–5.

Radioactive kinase assay

The radioactive kinase assay was performed at 19 °C in 25 mM Tris, pH 7.5, 50 mM NaCl, 2% glycerol, and 20 mM MgCl₂. 15 μM β -casein substrate was incubated with 1 μM McsB and/or other proteins (1 μM McsA, 5 μM YwIE) for 0, 30 and 120 min. The reaction was started by adding ATP (spiked with [γ -³²P]ATP from Perkin Elmer) to a final concentration

of 10 mM and stopped with denaturing SDS–PAGE sample buffer. After resolving the samples by SDS–PAGE, phosphorylation was visualized using phosphoimager technology (GE Healthcare Life Sciences).

ATPase assays

ATPase activity was determined by a coupled enzymatic reaction⁴⁷. 0.125–0.5 μM ClpC was incubated with 18.75 U ml^{-1} pyruvate kinase, 21.45 U ml^{-1} lactate dehydrogenase, 0.2–0.3 mM NADH, 7.5 mM phosphoenolpyruvate and 2 mM ATP in 20 mM HEPES, pH 7.5, 100 mM NaCl, and 5 mM MgCl_2 . Further assay proteins (MecA, McsB, McsA and β -casein) were added at 4–6-fold excess over ClpC. The absorption at 340 nm ($A_{340\text{ nm}}$) was recorded for 60 min using a Synergy H1 Multi-Mode Reader. The molar ATPase activity (ν) was calculated by the equation: $\nu = A_{340\text{ nm}} / (\text{path length} \times 6,220 \times [\text{ClpC}] \times \text{M}^{-1} \times \text{cm}^{-1})$. All activity data represent a minimum of three independent experiments and the variability is highlighted as standard deviation.

ITC

ITC measurements were performed using VP-ITC (Microcal). Ligands (pArg^{AA}, L-arginine, phospho-L-tyrosine (pTyr^{AA}, from Sigma), and sodium phosphate, pH 7.5, were prepared at 0.3–1.4 mM in 25 mM Tris, pH 8, 50 mM NaCl, 0.2 mM TCEP and titrated to a 20 μM ClpC^{DWB} (full-length) or 140 μM ClpC^{NTD} protein solution present in the same buffer. The same set-up was used for the analysis of ClpA^{NTD}. The following settings were used: 5 μl (first) and 10 μl (all subsequent injections) injection volume, 300 s spacing time between the injections, 300 r.p.m. stirring speed, 25 °C temperature and overflow mode. Control experiments were carried out to correct for dilution effects upon protein/ligand titration. Resulting data were analysed with the MicroCal ORIGIN software.

Structure determination of *B. subtilis* ClpC NTD in complex with pArg^{AA}

Crystals of a ClpC^{NTD}–pArg^{AA} complex were obtained by the sitting-drop vapour diffusion method upon mixing 100 nl of reservoir with 200 nl of a ClpC^{NTD} (2 mM) protein solution containing 2 mM pArg^{AA}. The optimized crystallization solution contained 13.5% (w/w) polyethylene glycol 4000, 500 mM ammonium sulfate, and 100 mM sodium acetate at pH 5. Crystals formed overnight at 19 °C and were soaked/cryo-protected in 40% polyethylene glycol 400, 20 mM Tris pH 8, and 6 mM pArg^{AA} before being flash-frozen. Diffraction data to 1.6 Å were collected at 100 K using a wavelength of 0.9763 Å at beamline P14, DESY, Hamburg and integrated with XDS⁴⁸. Molecular replacement in Phaser⁴⁹ using the NTD of ClpC from *B. subtilis* (PDB code 2Y1Q; ref. 29) as a search model yielded a high-confidence solution. Refinement in CNS⁵⁰, automatic rebuilding in Phenix⁵¹, and manual rebuilding in Coot^{52,53} were carried out, followed by placing of ligands in Coot⁵⁴. *N*(omega)-phospho-L-arginine structure and constraints were obtained with the respective SMILES code using eLBOW⁵⁵. Rounds of refinement in Phenix⁵⁶ and rebuilding in Coot yielded the final model with good statistics and geometry (Extended Data Table 2 and the following Ramachandran statistics: 98% favoured, 2% allowed, 0% outliers, 0% rotamer outliers). The featured-enhanced map, which is based on a composite residual omit map, was used to show ligand density. Figures were produced in Pymol⁵⁷.

Purification of *B. subtilis* protein aggregates

For the phosphoproteomic analysis of *B. subtilis* protein aggregates, a 3-l culture of *B. subtilis* was grown at 37 °C until late exponential phase and then heat-shocked (50 °C) for 45 min. Cells were collected by centrifugation, resuspended in 25 mM Tris, pH 7.5, 150 mM NaCl, 0.5% Triton X-100 and stored at –80 °C.

A 30-ml cell suspension in 25 mM Tris, pH 7.5, 150 mM NaCl, 0.5% Triton X-100 was incubated on ice with 3 mg ml⁻¹ lysozyme, Complete protease inhibitor cocktail (Roche), 20 µg ml⁻¹ DNase, 0.2 mM PMSF and 2 mM vanadate for 30 min. After dilution to 100 ml, cells were gently lysed at 4 °C by French Press (Constant Cell Disruption Systems) at 1.7 kbar. Lysis efficiency, estimated by plating out serial dilutions, exceeded 99%. The lysates were centrifuged at 45,000g for 30 min. The resulting pellets, containing insoluble protein aggregates, were further washed with 20 ml lysis buffer containing 0.4 mg ml⁻¹ lysozyme, 10 µg ml⁻¹ DNase, 0.2 mM PMSF and 2 mM vanadate. After 40 min homogenization at 4 °C under gentle agitation, the pellets were re-centrifuged. The protein aggregates contained in the pellets were then solubilized in 7 ml 25 mM Tris, pH 7.5, 8 M urea by sonication. The samples were again centrifuged to separate the urea-solubilized protein aggregates from cell debris. The resulting supernatants were stored at –80 °C until MS sample processing.

Thermotolerance assay

To test the role of ClpC during heat stress, the following *B. subtilis* strains were investigated: wild type + pHCMC05, *clpC::tet* + pHCMC05, *clpC::tet* + pHCMC05-ClpC and *clpC::tet* + pHCMC05-ClpC^{EA}. For all experiment, cultures were grown at 37 °C in LB media containing 10 µg ml⁻¹ chloramphenicol and 0.2 mM IPTG. After reaching exponential phase, the cultures were transferred to a pre-warmed incubator at 53 °C for 0, 30, 60 or 120 min, respectively. After heat stress, the samples were diluted sequentially and transferred to LB plates. To compare the survival rate after heat stress, we determined the number of colony-forming units (CFU). All experiments were independently performed three times and the observed variability is highlighted as standard deviation.


Native mass spectrometry

Native mass spectrometry experiments were carried out on a Synapt G2Si instrument (Waters) with a nanoelectrospray ionisation (nESI) source. Mass calibration was performed by a separate infusion of NaI cluster ions. Solutions were ionised through a positive potential applied to metal-coated borosilicate capillaries (Thermo Scientific). β-casein samples (5 µM) were sprayed from 25 mM ammonium acetate, pH 6.8. The temperature settings were capillary voltage 1.5 kV, sample cone voltage 30 V, extractor source offset 46 V, and source temperature 50 °C. Data were processed using Masslynx V4.1 software.

Data reporting

Source Data for Figs 1–5 are provided in the Supplementary Information. No statistical methods were used to predetermine sample size. The experiments were not randomized, and investigators were not blinded to allocation during experiments and outcome assessment.


Extended Data



Extended Data Figure 1. Development and validation of the ClpP^{X-TRAP} mutant.


a. Co-NTA purification of wild-type and TRAP mutant ClpP(6His) expressed in heat-stressed *B. subtilis* wild-type cells. SDS-PAGE (left) reveals co-purification of two ClpP protein species. MALDI-MS analysis (bottom) estimates that the mass difference between the two ClpP species was 1,036 and 1,042 Da for wild-type and TRAP ClpP, respectively. These values fit to the expected mass of the 6His tag (1,065 Da), indicating that the purified proteins correspond to recombinant (tagged) and endogenous ClpP. Native-PAGE (right) shows that the two proteins are present predominantly as a composite, heptameric complex.

Therefore, ClpP(6His)^{TRAP} expression in *B. subtilis* under heat-stress conditions is complicated by the formation of mixed complexes with endogenous (active) ClpP (cartoon). As the untagged endogenous ClpP was observed at similar levels as ClpP(6His), it is unlikely that efficient substrate-trapping complexes—built up exclusively by inactive ClpP^{TRAP}—are formed *in vivo*. **b**, Engineering of the ClpP cross mutant. Crystal structure of the ClpP heptamer (PDB code 3KTI; ref. 58) shown in top (left) and side (right) view. Zoomed-in picture shows interaction between Arg142 and Glu119 of two neighbouring subunits. To avoid the interaction of the recombinant ClpP(6His) trapping mutant with endogenous ClpP, these two residues were inter-exchanged (Glu119Arg/Arg142Glu), thus leading to an electrostatic repulsion between the cross-mutant ClpP(6His)^{X-TRAP} and wild-type ClpP, while allowing formation of the respective homo-heptamers, as schematically indicated. **c**, Co-NTA purification of ClpP(6His)^X and ClpP(6His)^{X-TRAP} expressed in heat-stressed *B. subtilis* wild-type cells. SDS-PAGE (left) shows that the X variants do not co-purify with endogenous ClpP, demonstrating that the Glu119Arg/Arg142Glu mutation prevents the formation of hetero-oligomers (as shown in the cartoon). Native-PAGE analysis (middle) suggests that the ClpP(6His)^X protein has a reduced heptamerization propensity. However, the inactive version (Ser98Ala, 'TRAP') of the ClpP(6His)^X mutant is present predominantly as a heptameric complex, probably owing to the stabilization by trapped substrates. ClpP(6His)^{X-TRAP} thus represents a tool to trap substrates in the wild-type background of *B. subtilis*. Our experimental approach has the advantage of avoiding the use of the *clpP* *B. subtilis* strain, which has an extremely pleiotropic phenotype (including increased levels of McsB and McsA¹⁴) that would largely bias the characterization of ClpP substrates. The ClpP^X protein represents the ideal negative control: it has reduced ability to heptamerize and therefore to degrade proteins, and its overexpression is expected to have little effect on the overall levels of protein degradation and consequently on the abundance of substrate proteins.



Extended Data Figure 2. *In vivo* characterization of ClpP^X-TRAP variants used in pull-down experiments.







a. SDS-PAGE (left) and native-PAGE (right) analysis of co-NTA purifications of experiment 1: pull-down of His-tagged ClpP variants in wild-type *B. subtilis*. Numbers denote biological replicates. Each sample represents approximately 10% of the total purification. **b.** SDS-PAGE (top) and native-PAGE (bottom) analysis of co-NTA purifications of experiment 2: pull-down of His-tagged ClpP variants in the wild-type (left) and *clpC* (right) *B. subtilis* strain. Each sample represents approximately 5% of the total purification.



Extended Data Figure 3. Preparation and validation of casein^{pArg} as a model substrate of ClpCP.

a, Top, size exclusion chromatography (SEC) separation of casein^{pArg} from the *B. subtilis* McsBA complex after *in vitro* phosphorylation. The red markings indicate the fractions that were pooled. Bottom, SDS-PAGE analysis of the fractions indicates that the SEC procedure could separate at least 95% of the McsB protein from the pooled β -casein fractions. **b**, Evaluating the effect of the McsB contamination on the degradation of casein^{pArg}. Top, ClpCP *in vitro* degradation assay towards untreated β -casein. Middle, ClpCP *in vitro*


degradation of casein^{pArg}, with and without additional McsB kinase. Bottom, addition of either inactive or active McsB did not have an effect on the initial degradation rate of casein^{pArg}. Of note, the degradation of untreated casein in the presence of McsBA is slightly delayed compared to the degradation of pre-modified casein^{pArg}. **c**, An alternative, improved protocol for purifying casein^{pArg}. After *in vitro* phosphorylation of β -casein by *G. stearothermophilus* McsB(6His), a Ni-NTA column was used to capture the tagged kinase. The flow-through fraction was then applied to a SEC column to further separate remaining McsB from β -casein. Two different fractions of the β -casein peak were collected, the later-eluting one (yellow) having a higher degree of purity in relation to the earlier one (orange). **d**, Activation of the ClpC ATPase activity by the different casein^{pArg} preparations (2 μ M concentration each). Each fraction contains a different (substoichiometric) amount of the McsB contamination. ATPase measurements reveal an almost identical activation of ClpC for all fractions, indicating that the residual amounts of McsB present in the casein^{pArg} sample do not contribute to ClpC activation. Error bars denote standard deviation of technical triplicates. **e**, To obtain substrate samples varying in the amount of arginine phosphorylation, casein was pre-incubated with McsBA for increasing times. The YwLE arginine phosphatase was added to the sample phosphorylated most strongly (120 min incubation with McsBA) as a negative control. The resultant casein^{pArg} samples were subjected to pArg immunoblots using a pArg-specific antibody²⁴ (right, top) and to ClpCP degradation assays (right, bottom).

McsB with pArg^{AA}MecA with pArg^{AA}ClpC^{DWB} (full-length)
with Arg^{AA} and NaPiClpC^{NTD} (1-150) with NaPiClpC^{NTD} (1-150) with Arg^{AA}ClpC^{NTD} (1-150) with pTyr^{AA}


structural alignment of the NTD's
from ClpC and ClpA




ClpA^{NTD} (1-150) with pArg^{AA}




ClpC^{NTD} with pArg^{AA}



ClpC^{NTD} (E32A/E106A)
with pArg^{AA}




ClpC^{NTD} (E32R/E106R/R9E/R83E)
with pArg^{AA}



Extended Data Figure 4. ITC binding data.


For each binding study, the analysed interactions are indicated on the top, and the respective K_d values, when detected, are shown below. For reference, a structural alignment of the ClpC (grey) and ClpA (purple; PDB code 1K6K) NTDs, showing a high degree of structural similarity, is presented.



Extended Data Figure 5. Binding pockets of pArg, pTyr and pSer/Thr.


The binding pockets are shown as surface representation and coloured according to their electrostatics as calculated with PyMol (blue: positive, red: negative). Bound phosphoamino acids are presented as sticks with nitrogens and oxygens coloured blue and red, respectively. **a, b**, pArg-binding sites 1 and 2, respectively, of the ClpC^{NTD} domain. The sites are characterized by a ‘bipolar’ architecture with both a positive and a negative area, jointly required to recognize a pArg side chain. **c, d**, pTyr-binding site of the Src SH2 domain (PDB code 1SPS; ref. 59) and pSer/Thr-binding site of the 14-3-3 domain (PDB code 1QJB; ref.

60). Both pTyr and pSer were part of a peptide but are shown in isolation for clarity. In contrast to the pArg-binding site, pTyr- and pSer/Thr-specific pockets are uniformly positively charged.



Extended Data Figure 6. Sequence alignment of the pArg-binding site of ClpC from different species and of the homologous regions of other Clp ATPases.

The two symmetrical regions (comprising residues 6–68 and 80–142, approximately) of each protein are aligned. Residues interacting with the pArg molecule (the Glu residue binding to the guanidinium group and the Arg/Thr residues interacting with the phosphate) are circled in black and marked by an arrow. Each of the two pArg-binding sites comprises Glu and Thr from one symmetrical region and Arg and Thr from the other. The alignment shows high conservation of the critical residues of ClpC proteins from different McsB-containing bacteria (*B. subtilis*, *Listeria monocytogenes*, *Staphylococcus aureus*, *Bacillus anthracis* and *Peptoclostridium difficile*). Conversely, the residues are not conserved in related Clp proteins (ClpA and ClpB) from McsB-deficient, Gram-negative bacteria.



Extended Data Figure 7. Intact mass analysis of McsB-treated and untreated (control) β -casein.

a, Unprocessed MS spectra. Zoomed view of the 13+ charge state species shows two predominant arginine phosphorylation states in the McsB-treated sample (top): 1 phosphorylation (diamond, m/z 1,852) and 2 phosphorylations (triangle, m/z 1,852), while only the non-pArg form (circle, m/z 1,848) can be visualized in the untreated control (bottom). **b**, Deconvoluted MS spectra, showing the average proportion of unmodified (circle, 23,982 Da), 1 pArg-containing (diamond, 24,063 Da) and 2 pArg-containing (triangle, 24,142 Da) β -casein.

Extended Data Table 1
Summary of identified phosphosites in various ClpP
trapping experiments.

Uniprot	Gene Id	Protein Descriptions	Experiment 1		Experiment 2			
			<i>B. subtilis</i>	wt	<i>B. subtilis</i>	wt	<i>B. subtilis</i>	<i>clpC</i>
			control	TRAP	control	TRAP	control	TRAP
Arg-phosphorylated proteins								
P71006	albF	Putative zinc protease AlbF		R17				
P37941	bfmBAB	2-oxoisovalerate dehydrogenase subunit b				R23		
O32222	csor	Cu-sensing transcriptional repressor CsoR		R24		R24		
P37568	ctsR	Transcriptional regulator CtsR		R55		R55		R55
P42416	iolE	Inosose dehydratase		R216				
O34645	melA	Alpha-galactosidase		R56		R56		
O34338	mntB	Mn transport ATP-binding prot. MntB		R132, (R73)		R132		
P16263	odhB	2-oxoglutarate dehydrogenase E2				R300		
P12875	rplN	50S ribosomal prot. L14		R17		R17		
P42060	rplV	50S ribosomal prot. L22		R11				
P12879	rpsH	30S ribosomal prot. S8		R47, R72, R79		R47, R72		
P27206	srfAA	Surfactin synthase subunit 1		R226		R226		
P33166	tuf	Elongation factor Tu		R384				
O34909	yerA	Putative adenine deaminase YerA				R14		
O34949	ykoM	Uncharact. HTH-type transcript. regulator YkoM						R89
P42430	ykyB	Uncharacterized prot. YkyB				R26		R26
P54391	ypiF	Uncharacterized prot. YpiF	R4					
O07019	yvfU	Uncharact. transcript. regulatory protein YvfU				R143		
Phosphorylated proteins, likely pArg								
P13800	degU	Transcriptional regulatory prot. DegU				(R184)		
P25499	hrcA	Heat-inducible Transcriptional repressor HrcA		(R27)		(R27)		
Ser/Thr/Tyr-phosphorylated proteins								
P25953	comGA	ComG operon prot. 1						T178
O31461	ilvE	Branched-chain aa transaminase 1	T249					
P42956	mtlA	PTS system mannitol-specific EIICB	S365					S365
P55874	rpmI	50S ribosomal prot. L35			S47		S47	

Uniprot	Gene Id	Protein Descriptions	Experiment 1		Experiment 2				
			<i>B. subtilis</i>	wt	<i>B. subtilis</i>	wt	<i>B. subtilis</i>	<i>clpC</i>	
			control	TRAP	control	TRAP	control	TRAP	
P21476	rpsS	30S ribosomal prot. S19			T77				
O34607	sdaAA	Probable L-serine dehydratase, α chain							T99
P54334	xkdO	Phage-like element PBSX prot. XkdO						S295	
O34833	yceH	Uncharacterized prot. YceH			S296	S296	S296	S296	S296
O32131	yunB	Sporulation prot. YunB	T165						
P39808	yvyG	Uncharacterized prot. YvyG			Y49	Y49	Y49	Y49	Y49
P42294	yxiB	Uncharacterized prot. YxiB				S88			

Extended Data Table 2
Summary of crystallographic data collection and analysis.

Data collection	
Wavelength (Å)	0.9763
Resolution range (Å)	42.3 - 1.60 (1.66 - 1.60)
Space group	P 65
Unit cell	
<i>a, b, c</i> (Å)	84.6, 84.6, 29.85
<i>a, β, γ</i> (°)	90, 90, 120
Total reflections	298,317 (14,879)
Unique reflections	16,055 (1,350)
Multiplicity	18.6 (11.0)
Completeness (%)	0.98 (0.83)
Mean <i>I</i> / σ (<i>I</i>)	29.62 (4.73)
Wilson B-factor	20.61
R-merge	0.062 (0.55)
R-meas	0.064 (0.58)
R-pim	0.015 (0.17)
CC1/2	0.999 (0.95)
CC*	1 (0.987)

Data collection	
Structure Refinement	
Reflections used in refinement	16,041 (1,349)
Reflections used for R-free	1,585 (133)
R-work	0.145 (0.195)
R-free	0.166 (0.253)
Number of non-hydrogen atoms	
total	1,264
macromolecules	1,147
ligands	77
Protein residues	145
R.M.S. deviations	
bond lengths (Å)	0.009
angles (°)	0.97
Ramachandran favored (%)	98
Ramachandran allowed (%)	2
Ramachandran outliers (%)	0
Rotamer outliers (%)	0
Clashscore	3.30
Average B-factor (overall)	28.7
protein	28.1
ligands	35.1
solvent	36.3

Extended Data Table 3
Expression and purification conditions

Protein	Expression	Buffer A	Buffer B
<i>Bs</i> ClpC	37°C, 3h	25 mM Tris pH 7.5, 300 mM NaCl	25 mM Tris pH 7.5, 300 mM NaCl
<i>Bs</i> ClpC ^{DWB}	37°C, 3h	25 mM Tris pH 8, 300 mM NaCl	25 mM Tris pH 7.5, 300 mM NaCl
<i>Bs</i> ClpC ^{NTD}	37°C, 2h	25 mM Tris pH 8.5, 150 mM NaCl, 1 mM TCEP	5 mM Tris pH 8.5, 50 mM NaCl, 1 mM TCEP
<i>Ec</i> ClpA ^{NTD}	37°C, 2h	25 mM Tris pH 8.5, 150 mM NaCl, 1 mM TCEP	5 mM Tris pH 8.5, 50 mM NaCl, 1 mM TCEP
<i>Bs</i> ClpP	37°C, 3h	25 mM Tris pH 7.5, 150 mM NaCl, 10% glycerol	25 mM Tris pH 7.5, 150 mM NaCl, 10% glycerol
<i>Bs</i> McsA	20°C, 5h	25 mM Tris pH 7.5, 300 mM NaCl, TCEP 1 mM	25 mM Tris pH 7.5, 100 mM NaCl, TCEP 1 mM

Protein	Expression	Buffer A	Buffer B
<i>Bs</i> McsB	18°C, O/N	25 mM Tris pH 7.5, 300 mM KCl	25 mM Tris pH 7.5, 50 mM KCl
<i>Bs</i> McsB ^{E212A}	18°C, O/N	25 mM Tris pH 7.5, 300 mM KCl	25 mM Tris pH 7.5, 50 mM KCl
<i>Gs</i> McsB	37°C, 3h	25 mM Hepes pH 7.5, 300 mM KCl	25 mM Hepes pH 7.5, 100 mM KCl
<i>Gs</i> McsB ^{E122A}	18°C, O/N	50 mM Tris pH 7.5, 50 mM NaCl	50 mM Tris pH 7.5, 50 mM NaCl
<i>Bs</i> MecA	25°C, 5h	25 mM Hepes pH 8, 300 mM KCl	25 mM Hepes pH 8, 300 mM KCl
<i>Gs</i> YwIE	37°C, 3h	25 mM Tris pH 7.5, 300 mM NaCl	25 mM Tris pH 7.5, 100 mM NaCl
<i>Gs</i> YwIE ^{D118N}	37°C, 3h	25 mM Tris pH 7.5, 300 mM NaCl	25 mM Tris pH 7.5, 100 mM NaCl

Bs: *Bacillus subtilis*, *Ec*: *Escherichia coli*, *Gs*: *Geobacillus stearothermophilus*, O/N: overnight

Acknowledgements

We thank E. Charpentier for providing *B. subtilis* strains and plasmids, S. Spiess for advice on *B. subtilis* genetic manipulation, G. Dürnberger for assistance with statistical analysis, A. Schmidt for help with mass spectrometry interpretation, R. Beveridge for performing native mass spectrometry analysis, J. Kley for help with ITC experiments and G. Bourenkov and T. Schneider at DESY for assistance during data collection. This work was supported by the Austrian Research Promotion Agency (FFG). The IMP is funded by Boehringer Ingelheim.

References

- Goldberg AL. The mechanism and functions of ATP-dependent proteases in bacterial and animal cells. *Eur J Biochem.* 1992; 203:9–23. [PubMed: 1730246]
- Löwe J, et al. Crystal structure of the 20S proteasome from the archaeon *T. acidophilum* at 3.4 Å resolution. *Science.* 1995; 268:533–539. [PubMed: 7725097]
- Glickman MH, et al. A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. *Cell.* 1998; 94:615–623. [PubMed: 9741626]
- Elsasser S, Finley D. Delivery of ubiquitinated substrates to protein-unfolding machines. *Nat Cell Biol.* 2005; 7:742–749. [PubMed: 16056265]
- Kerscher O, Felberbaum R, Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. *Annu Rev Cell Dev Biol.* 2006; 22:159–180. [PubMed: 16753028]
- Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. *Annu Rev Biochem.* 2009; 78:477–513. [PubMed: 19489727]
- Burns KE, Liu WT, Boshoff HI, Dorrestein PC, Barry CE. III. Proteasomal protein degradation in *Mycobacteria* is dependent upon a prokaryotic ubiquitin-like protein. *J Biol Chem.* 2009; 284:3069–3075. [PubMed: 19028679]
- Pearce MJ, Mintseris J, Ferreyra J, Gygi SP, Darwin KH. Ubiquitin-like protein involved in the proteasome pathway of *Mycobacterium tuberculosis*. *Science.* 2008; 322:1104–1107. [PubMed: 18832610]
- Battesti A, Gottesman S. Roles of adaptor proteins in regulation of bacterial proteolysis. *Curr Opin Microbiol.* 2013; 16:140–147. [PubMed: 23375660]
- Flynn JM, Neher SB, Kim YI, Sauer RT, Baker TA. Proteomic discovery of cellular substrates of the ClpXP protease reveals five classes of ClpX-recognition signals. *Mol Cell.* 2003; 11:671–683. [PubMed: 12667450]
- Sauer RT, Baker TA. AAA+ proteases: ATP-fueled machines of protein destruction. *Annu Rev Biochem.* 2011; 80:587–612. [PubMed: 21469952]
- Keiler KC, Waller PR, Sauer RT. Role of a peptide tagging system in degradation of proteins synthesized from damaged messenger RNA. *Science.* 1996; 271:990–993. [PubMed: 8584937]
- Fuhrmann J, et al. McsB is a protein arginine kinase that phosphorylates and inhibits the heat-shock regulator CtsR. *Science.* 2009; 324:1323–1327. [PubMed: 19498169]

14. Krüger E, Zühlke D, Witt E, Ludwig H, Hecker M. Clp-mediated proteolysis in Gram-positive bacteria is autoregulated by the stability of a repressor. *EMBO J.* 2001; 20:852–863. [PubMed: 11179229]
15. Schmidt A, et al. Quantitative phosphoproteomics reveals the role of protein arginine phosphorylation in the bacterial stress response. *Mol Cell Proteomics.* 2014; 13:537–550. [PubMed: 24263382]
16. Derré I, Rapoport G, Msadek T. CtsR, a novel regulator of stress and heat shock response, controls clp and molecular chaperone gene expression in gram-positive bacteria. *Mol Microbiol.* 1999; 31:117–131. [PubMed: 9987115]
17. Kirstein J, Dougan DA, Gerth U, Hecker M, Turgay K. The tyrosine kinase McsB is a regulated adaptor protein for ClpCP. *EMBO J.* 2007; 26:2061–2070. [PubMed: 17380125]
18. Elsholz AK, Michalik S, Zühlke D, Hecker M, Gerth U. CtsR, the Gram-positive master regulator of protein quality control, feels the heat. *EMBO J.* 2010; 29:3621–3629. [PubMed: 20852588]
19. Elsholz AK, et al. Global impact of protein arginine phosphorylation on the physiology of *Bacillus subtilis*. *Proc Natl Acad Sci USA.* 2012; 109:7451–7456. [PubMed: 22517742]
20. Boisvert FM, Chénard CA, Richard S. Protein interfaces in signaling regulated by arginine methylation. *Sci STKE.* 2005; 2005:re2. [PubMed: 15713950]
21. Feng J, et al. Trapping and proteomic identification of cellular substrates of the ClpP protease in *Staphylococcus aureus*. *J Proteome Res.* 2013; 12:547–558. [PubMed: 23253041]
22. Miethke M, Hecker M, Gerth U. Involvement of *Bacillus subtilis* ClpE in CtsR degradation and protein quality control. *J Bacteriol.* 2006; 188:4610–4619. [PubMed: 16788169]
23. Derré I, Rapoport G, Msadek T. The CtsR regulator of stress response is active as a dimer and specifically degraded in vivo at 37 degrees C. *Mol Microbiol.* 2000; 38:335–347. [PubMed: 11069659]
24. Fuhrmann J, et al. Structural basis for recognizing phosphoarginine and evolving residue-specific protein phosphatases in Gram-positive bacteria. *Cell Reports.* 2013; 3:1832–1839. [PubMed: 23770242]
25. Trentini DB, Fuhrmann J, Mechtler K, Clausen T. Chasing phosphoarginine proteins: development of a selective enrichment method using a phosphatase trap. *Mol Cell Proteomics.* 2014; 13:1953–1964. [PubMed: 24825175]
26. Schlothauer T, Mogk A, Dougan DA, Bukau B, Turgay K. MecA, an adaptor protein necessary for ClpC chaperone activity. *Proc Natl Acad Sci USA.* 2003; 100:2306–2311. [PubMed: 12598648]
27. Kirstein J, Zühlke D, Gerth U, Turgay K, Hecker M. A tyrosine kinase and its activator control the activity of the CtsR heat shock repressor in *B. subtilis*. *EMBO J.* 2005; 24:3435–3445. [PubMed: 16163393]
28. Kojetin DJ, et al. Structural and motional contributions of the *Bacillus subtilis* ClpC N-domain to adaptor protein interactions. *J Mol Biol.* 2009; 387:639–652. [PubMed: 19361434]
29. Wang F, et al. Structure and mechanism of the hexameric MecA-ClpC molecular machine. *Nature.* 2011; 471:331–335. [PubMed: 21368759]
30. Woo KM, Kim KI, Goldberg AL, Ha DB, Chung CH. The heat-shock protein ClpB in *Escherichia coli* is a protein-activated ATPase. *J Biol Chem.* 1992; 267:20429–20434. [PubMed: 1400361]
31. Hagai T, Levy Y. Ubiquitin not only serves as a tag but also assists degradation by inducing protein unfolding. *Proc Natl Acad Sci USA.* 2010; 107:2001–2006. [PubMed: 20080694]
32. Kirstein J, et al. Adaptor protein controlled oligomerization activates the AAA+ protein ClpC. *EMBO J.* 2006; 25:1481–1491. [PubMed: 16525504]
33. Stannek L, Gunka K, Care RA, Gerth U, Commichau FM. Factors that mediate and prevent degradation of the inactive and unstable GudB protein in *Bacillus subtilis*. *Front Microbiol.* 2015; 5:758. [PubMed: 25610436]
34. Chan P, Curtis RA, Warwick J. Soluble expression of proteins correlates with a lack of positively-charged surface. *Sci Rep.* 2013; 3
35. Nguyen HD, et al. Construction of plasmid-based expression vectors for *Bacillus subtilis* exhibiting full structural stability. *Plasmid.* 2005; 54:241–248. [PubMed: 16005967]

36. Gerth U, et al. Fine-tuning in regulation of Clp protein content in *Bacillus subtilis*. *J Bacteriol.* 2004; 186:179–191. [PubMed: 14679237]
37. Msadek T, et al. ClpP of *Bacillus subtilis* is required for competence development, motility, degradative enzyme synthesis, growth at high temperature and sporulation. *Mol Microbiol.* 1998; 27:899–914. [PubMed: 9535081]
38. Wi niewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. *Nat Methods.* 2009; 6:359–362. [PubMed: 19377485]
39. Käll L, Canterbury JD, Weston J, Noble WS, MacCoss MJ. Semi-supervised learning for peptide identification from shotgun proteomics datasets. *Nat Methods.* 2007; 4:923–925. [PubMed: 17952086]
40. Taus T, et al. Universal and confident phosphorylation site localization using phosphoRS. *J Proteome Res.* 2011; 10:5354–5362. [PubMed: 22073976]
41. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat Biotechnol.* 2008; 26:1367–1372. [PubMed: 19029910]
42. Cox J, et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. *J Proteome Res.* 2011; 10:1794–1805. [PubMed: 21254760]
43. Cox J, et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. *Mol Cell Proteomics.* 2014; 13:2513–2526. [PubMed: 24942700]
44. Vizcaíno JA, et al. The PRoteomics IDentifications (PRIDE) database and associated tools: status in 2013. *Nucleic Acids Res.* 2013; 41:D1063–D1069. [PubMed: 23203882]
45. Suzuki Y, Takeda Y, Ikuta T. Immunoblotting conditions for human hemoglobin chains. *Anal Biochem.* 2008; 378:218–220. [PubMed: 18445469]
46. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. *Nat Methods.* 2012; 9:671–675. [PubMed: 22930834]
47. Nørby JG. Coupled assay of Na⁺,K⁺-ATPase activity. *Methods Enzymol.* 1988; 156:116–119. [PubMed: 2835597]
48. Kabsch W. Xds. *Acta Crystallogr D.* 2010; 66:125–132. [PubMed: 20124692]
49. McCoy AJ, et al. Phaser crystallographic software. *J Appl Crystallogr.* 2007; 40:658–674. [PubMed: 19461840]
50. Brünger AT, et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. *Acta Crystallogr D.* 1998; 54:905–921. [PubMed: 9757107]
51. Terwilliger TC, et al. Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. *Acta Crystallogr D.* 2008; 64:61–69. [PubMed: 18094468]
52. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. *Acta Crystallogr D.* 2004; 60:2126–2132. [PubMed: 15572765]
53. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. *Acta Crystallogr D.* 2010; 66:486–501. [PubMed: 20383002]
54. Debreczeni JE, Emsley P. Handling ligands with Coot. *Acta Crystallogr D.* 2012; 68:425–430. [PubMed: 22505262]
55. Moriarty NW, Grosse-Kunstleve RW, Adams PD. electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation. *Acta Crystallogr D.* 2009; 65:1074–1080. [PubMed: 19770504]
56. Adams PD, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D.* 2010; 66:213–221. [PubMed: 20124702]
57. Schrodinger, LLC. The PyMOL Molecular Graphics System v.1.3r1. 2010.
58. Lee BG, et al. Structures of ClpP in complex with acyldepsipeptide antibiotics reveal its activation mechanism. *Nat Struct Mol Biol.* 2010; 17:471–478. [PubMed: 20305655]
59. Waksman G, Shoelson SE, Pant N, Cowburn D, Kuriyan J. Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: crystal structures of the complexed and peptide-free forms. *Cell.* 1993; 72:779–790. [PubMed: 7680960]

60. Rittinger K, et al. Structural analysis of 14-3-3 phosphopeptide complexes identifies a dual role for the nuclear export signal of 14-3-3 in ligand binding. *Mol Cell*. 1999; 4:153–166. [PubMed: 10488331]




Figure 1. Pull-down of ClpP trapping mutants.

a, Cartoon illustrating the experimental workflow. As indicated, all pull-down experiments were done in triplicates. LC-MS/MS, liquid chromatography tandem mass spectrometry. **b**, Volcano plot illustrating proteins identified in ClpP^X (control) and ClpP^{X-TRAP} pull-downs after expression in a *B. subtilis* wild-type (WT) strain. Proteins were considered as ClpP substrates (shaded area) when the X-TRAP/control relative protein intensity (x axis) was >2 and the corresponding limma P value (y axis) was <0.05 . Phosphorylated proteins are shown as filled squares (red: pArg, blue: pSer/Thr/Tyr). In a few cases, the phosphorylated residue could not be unambiguously localized. As the same phosphopeptides have been observed to

contain a pArg in previous experiments, they are labelled as probable pArg (open red squares). Identified pArg proteins are listed on the left. **c**, Volcano plots of the ClpP pull-downs performed in *B. subtilis* wild-type and *clpC* strains in parallel. For comparison, pArg proteins identified in the *B. subtilis* wild-type pull-downs are marked in yellow/orange in the *clpC* plot.




Figure 2. Effect of McsB on the activity of ClpCP *in vitro*.

a. ClpCP-mediated degradation of β -casein in the presence of different effector proteins. Here and in the following, a quantification of the β -casein band is presented (original SDS-PAGE gels in Supplementary Fig. 2). Bottom panel shows the kinase activity of assayed McsB variants in an autoradiography plot. **b.** In contrast to active McsB, the inactive McsB^{E212A} kinase cannot stimulate casein degradation by ClpCP. **c.** Effect of the YwIE arginine phosphatase on ClpCP activation by McsBA. The inactive YwIE^{D118N} mutant was used as a negative control.




Figure 3. Binding of pArg^{AA} to ClpC.

a, b, Inhibitory effect of pArg^{AA} on McsBA-activated (**a**) and MecA-activated (**b**) ClpCP. **c**, Pull-down experiment monitoring the interaction of the NTD (wild type and E32A/E106A mutant) with MecA (10 µM each) in the presence pArg^{AA}. **d**, ITC profile of pArg^{AA} binding to full-length double Walker B mutant ClpC (ClpC^{DWB(FL)}; left) and the NTD of ClpC (ClpC^{NTD(1-150)}; right). Determined K_d values are indicated.




Figure 4. ClpCP protease activity towards a pArg-containing substrate protein.

a, Preparation of the casein^{pArg} model substrate. SEC, size exclusion chromatography. **b**, Binding of casein^{pArg} (35 μ M) to ClpC NTD (10 μ M) at increasing amounts of pArg^{AA}. **c**, Degradation of casein^{pArg} by ClpCP without adaptor proteins and the inhibitory effect of pArg^{AA} on this activity. **d**, Pull-down experiment monitoring ClpCP complex formation in the presence of MecA, casein and casein^{pArg}. **e**, Preparation of substrate samples that contain increasing amounts of casein^{pArg} after prolonged incubation with McsBA. ClpCP degradation of resultant casein^{pArg} samples is directly correlated to the degree of substrate phosphorylation seen in pArg immunoblots (Extended Data Fig. 3e). AU, arbitrary units.




Figure 5. Crystal structure of the ClpC NTD in complex with pArg.

a, Overall structure of the ClpC NTD domain bound to two pArg^{AA} molecules. The cartoon representation is coloured in light grey (residues 70–148) and dark grey (4–69) to highlight the two symmetrical halves of the NTD. **b, c**, Zoomed view of pArg-binding sites 1 (**b**) and 2 (**c**), with labelled interacting residues. The $2F_o - F_c$ omit electron densities of the pArg^{AA} ligands, calculated at 1.6 Å resolution, are contoured at 1σ . **d**, Overlap of MecA- and pArg-binding sites. Shown is the hexameric organization of the ClpC^{1–485} (grey) complex with MecA^{121–218} (blue) (PDB code 3PXG; ref. 29) superimposed with pArg^{AA} (orange). Bottom left, zoomed-in view shows two adjacent ClpC NTDs with pArg^{AA} and MecA interactors. Bottom right, zoomed-in view illustrates that the pArg phosphoryl group and Glu184 (Glu198 in second binding site) of MecA compete for the same ClpC binding pocket. **e**, Scheme representing the distinct substrate (S) preferences of the wild-type ClpCP and ClpCP^{EA} protease complexes. **f**, Degradation assays comparing the activity of wild-type ClpCP and ClpCP^{EA} towards MecA-delivered (left) and pArg-labelled (middle, right) casein. YwIE was used as a control for the pArg-dependent degradation. **g**, ATPase activity of ClpC and ClpC^{EA} in the presence of putative substrate proteins. Levels are normalized to the induced ATPase activity of the ClpC–casein^{pArg} complex. Error bars show the s.d. of three independent experiments.




Figure 6. The pArg–ClpCP degradation system.

a, Thermotolerance assay analysing the *in vivo* complementation of *clpC* by expressing ClpC and ClpC^{EA}. Levels are normalized to the values before heat shock (time 0), and numbers above bars represent the fraction of cells surviving after 2 h heat shock. CFU, colony-forming units. Error bars show the s.d. of three independent experiments. **b**, The pArg–ClpCP system. Left, cartoon representation shows that after phosphorylation by the McsB arginine kinase, pArg-tagged proteins are targeted to the ClpCP protease. Binding of pArg proteins to one of the 12 NTD binding pockets stimulates the ATPase activity of ClpC,

leading to the translocation of the captured substrate into the ClpP protease cage and to protein degradation. Right, a model of the respective ClpCP complex (ClpC NTD in light grey, ClpC AAA1/2 in white, ClpP in dark grey, substrate in black).